Biodexa Pharmaceuticals Plc ADR (BDRX) concluded trading on Wednesday at a closing price of $8.40, with 7.29 million shares of worth about $61.25 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -60.49% during that period and on October 16, 2024 the price saw a gain of about 67.66%. Currently the company’s 20.33M shares are available for trading.
Stock saw a price change of 75.37% in past 5 days and over the past one month there was a price change of -11.81%. Year-to-date (YTD), BDRX shares are showing a performance of -87.46% which decreased to -92.55% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $4.71 but also hit the highest price of $220.25 during that period. The average intraday trading volume for Biodexa Pharmaceuticals Plc ADR shares is 31.41K. The stock is currently trading 28.33% above its 20-day simple moving average (SMA20), while that difference is down -19.38% for SMA50 and it goes to -67.16% lower than SMA200.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock has a 3Y-monthly beta is at 1.44. It has posted earnings per share of -$49.74 in the same period. It has Quick Ratio of 2.16 while making debt-to-equity ratio of 0.04. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for BDRX, volatility over the week remained 20.20% while standing at 16.80% over the month.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Ladenburg Thalmann on February 08, 2024 offering a Buy rating for the stock and assigned a target price of $8 to it.
